NCT01969643: A Safety Study of SGN-LIV1A in Breast Cancer Patients

NCT01969643
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Malignant CNS disease that has not been definitively treated
https://ClinicalTrials.gov/show/NCT01969643

Comments are closed.

Up ↑